Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525057 · ClinicalTrials.gov registry record · NA
Dalteparin in Preventing DVT in Participants With Cancer
A NA study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 65
- Enrollment target
NCT00525057: Completed NA study, sponsored by M.D. Anderson Cancer Center.
NCT00525057 is a NA study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 65 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00525057, a NA study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 65 participants
- Enrollment target
Study Summary
This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
Interventions
- DRUG Dalteparin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2006-07-07 |
| Est. Completion | 2020-06-19 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525057
The ClinicalTrials.gov registry entry for NCT00525057 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 65 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dalteparin is the first listed.
NCT00525057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525057 about?
NCT00525057 is a clinical study titled "Dalteparin in Preventing DVT in Participants With Cancer". This trial studies how well dalteparin works in preventing deep vein thrombosis (DVT) (blood clots) in participants with cancer. Dalteparin is a blood thinner that can treat blood clots and may prevent them from forming.
What is the current status of trial NCT00525057?
This trial is currently completed. It is a NA study. The enrollment target is 65 participants. The study started on 2006-07-07. Estimated completion is 2020-06-19.
What interventions are being tested in trial NCT00525057?
The interventions under investigation include: Dalteparin (DRUG).
Who is sponsoring clinical trial NCT00525057?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.